MedTrace Logo

Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

NCT01603355 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-01-14

Study results available
· View outcomes & findings →

Summary

The investigators are doing this research study to see if tocilizumab (Actemra) is safe and effective when used for severe or refractory non-infectious uveitis. Uveitis is an inflammation of the eye that is caused by the body's immune system reacting against the eye tissues.

Conditions

  • Juvenile Idiopathic Arthritis Associated Uveitis

Interventions

DRUG

Tocilizumab

Intravenous tocilizumab: Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Eric B. Suhler

    lead OTHER

Principal Investigators

  • Eric B Suhler, MD,MPH · Oregon Health and Science University

  • James T Rosenbaum, MD · Oregon Health and Science University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01603355 on ClinicalTrials.gov